Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DMBU | ISIN: DK0061804697 | Ticker-Symbol: LDBB
Tradegate
06.06.25 | 11:13
4,320 Euro
+5,11 % +0,210
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
H LUNDBECK A/S A Chart 1 Jahr
5-Tage-Chart
H LUNDBECK A/S A 5-Tage-Chart
RealtimeGeldBriefZeit
4,2554,34016:41
4,2654,28016:38

Aktuelle News zur H LUNDBECK A/S A Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
29.05.Lundbeck Foundation: The Brain Prize: HM The King of Denmark presents prestigious prize to US and German scientists for seminal discoveries in brain cancer234Two pioneering scientists received The Brain Prize 2025 for their discoveries that open an entirely new way of thinking about and understanding brain cancers, and the potential strategies...
► Artikel lesen
22.05.H. Lundbeck A/S: Lundbeck successfully places a EUR 500 million Eurobond765Valby, Denmark, 22 May 2025 - H. Lundbeck A/S (Lundbeck) has successfully placed an aggregate principal amount of EUR 500 million senior unsecured notes with a tenor of four (4) years maturing 2 June...
► Artikel lesen
14.05.H. Lundbeck A/S: Lundbeck raises financial guidance following strong start to the year with strategic brands growth of +24% CER155Key highlights Lundbeck's total revenue grew by +16% CER[1] (+18% DKK) to DKK 6,235 million in the first quarter of 2025, with all regions contributing to growth United States: DKK 3,284 million...
► Artikel lesen
H LUNDBECK A/S A Aktie jetzt für 0€ handeln
08.05.H. Lundbeck A/S: Lundbeck to share pipeline data and key insights into the progression of rare disease, Multiple System Atrophy, at International MSA Congress in Boston327VALBY, Denmark, May 8, 2025 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) will present key pipeline data and patient perspectives from the phase II AMULET trial, investigating amlenetug as a...
► Artikel lesen
06.05.H. Lundbeck A/S: Lundbeck joins forces with Danish Centre for AI Innovation to improve brain health by advancing drug discovery with Gefion AI supercomputer217VALBY, Denmark, May 6, 2025 /PRNewswire/ -- H. Lundbeck A/S is pleased to announce its agreement with the Danish Centre for AI Innovation (DCAI), the company established to run and operate...
► Artikel lesen
04.04.H. Lundbeck A/S: Lundbeck to present positive pipeline data at American Academy of Neurology (AAN) Annual Meeting488VALBY, Denmark, April 4, 2025 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) will present positive interim results from the open-label extension of the PACIFIC trial investigating bexicaserin...
► Artikel lesen
02.04.Lundbeck shares dop 6% as Deutsche Bank downgrades stock to "hold"15
02.04.Deutsche Bank cuts Lundbeck stock rating, lowers price target49
01.04.Lundbeck ends subcutaneous migraine cohort after futility review, pivots to IV formulation3
31.03.H. Lundbeck A/S: Following a planned interim analysis in the PROCEED trial Lundbeck expands the dose finding to intravenous administration of Lu AG09222 in migraine prevention298PROCEED is an adaptive Phase IIb trial with Lu AG09222, an investigational mAb intended to block signaling by pituitary adenylate cyclase-activating polypeptide (PACAP), a neuropeptide that...
► Artikel lesen
27.03.Dividendenbekanntmachungen (27.03.2025)10.859 Unternehmen  ISIN-Code  Dividende (Währung)  Dividende (EUR)  ABERDEEN GROUP PLC  GB00BF8Q6K64  0,073 GBP  0,0875 EUR  AFRICA OIL CORP  CA00829Q1019  0,0371 USD  0,0345 EUR  AGL ENERGY LIMITED  AU000000AGL7  0...
► Artikel lesen
26.03.H. Lundbeck A/S: Lundbeck held its Annual General Meeting on 26 March 2025 at the company's registered office495VALBY, Denmark, March 26, 2025 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) announced today that the report by the Board of Directors was adopted and the annual report was approved at the annual...
► Artikel lesen
25.03.Carl Zeiss Meditec, Lundbeck: Dividenden im global market - Ex-Tag 27.03.202549
14.03.EC approves Otsuka and Lundbeck's Rxulti for schizophrenia4
13.03.H. Lundbeck A/S: Rxulti (brexpiprazole) approved in the European Union for the treatment of schizophrenia in adolescents aged 13 years and older504Brexpiprazole's indication for the treatment of schizophrenia in adults is extended to include adolescents aged 13 years and older1Approval follows a positive Committee for Medicinal Products...
► Artikel lesen
13.03.H. LUNDBECK A/S: Rxulti[®] (brexpiprazole) approved in the European Union for the treatment of schizophrenia in adolescents aged 13 years and older3
11.03.Lundbeck's amlenetug gains orphan drug status in Japan for MSA1
10.03.H. Lundbeck A/S: Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan339VALBY, Denmark, March 10, 2025 /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug...
► Artikel lesen
25.02.H. Lundbeck A/S: To the shareholders of H. Lundbeck A/S229Notice of Annual General Meeting Notice is hereby given of the annual general meeting of H. Lundbeck A/S to be held on: Wednesday, 26 March 2025 at 10:00 am CET The annual general meeting will be...
► Artikel lesen
21.02.H. LUNDBECK A/S: Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties5
Weiter >>
36 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1